A panel of European Medicines Agency (EMA) has recommended granting conditional marketing approval to Clovis Oncology's drug for ovarian cancer, citing anti-tumour activity.
However, the EMA's Committee for Medicinal Products for Human Use (CHMP) listed fatigue, nausea, creatinine elevations and liver enzymes elevations https://goo.gl/fQ9iJh as most common side effects of the drug.
Like Tesaro Inc's niraparib and AstraZeneca's lynparza, the drug belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.
The panel also proposed that the drug should be prescribed by physicians experienced in the use of anti-cancer medicines.
CMPH's opinions are normally endorsed by the European Commission within a couple of months.
According to the report by American Cancer Society, over the past two decades, ovarian cancer incidence rates have been decreasing by about 1 percent per year among white women and by 0.4 percent in black women.
An estimated 14,080 ovarian cancer deaths were reported in 2017.Ovarian cancer accounts for 5 percent of cancer death among women, causing more deaths by any other gynecologic cancer.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)